Axe Compute Inc. (AGPU): Nasdaq/NYSE listing notice — Predictive Oncology receives Nasdaq delisting notice for failure to meet equity requirement

Axe Compute Inc.

Nasdaq notified Predictive Oncology June 9 of delisting for failing to meet $2.5M stockholders' equity requirement.
Company could not complete compliance plan within 180-day extension granted by Nasdaq.
Trading suspended June 18 unless appeal requested by June 16; company appealed to Nasdaq Hearings Panel.
Appeal stays suspension; Panel may grant exception up to 180 days.
No assurance of continued listing; company evaluating all options.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Axe Compute Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

June 9, 2025, Predictive Oncology Inc. (the “Company”) received a letter (the “Notice) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that because the Company had not regained compliance with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”), the Staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Company was unable to complete its previou

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Axe Compute Inc. filing history →

Source: SEC EDGAR

accession 0001171843-25-003836

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.